Comunicados de Imprensa
Elekta and Brainlab Collaborate to Enhance Radiosurgery Planning Power
STOCKHOLM and CHICAGO, Oct. 8 /PRNewswire/ – At the opening of the 2012 Congress of Neurological Surgeons (CNS) Annual Meeting in Chicago, radiosurgery and neurosurgery innovators Elekta and Brainlab, announced a collaboration which will enable neurosurgeons and radiation oncologists to use Brainlab’s iPlan® software together with Elekta’s Leksell GammaPlan® treatment planning for Gamma Knife® radiosurgery.
Through the collaboration, clinicians will be given the option to add the functionality of iPlan RT Image to the optimized dosimetry and precision of Leksell GammaPlan treatment planning. iPlan, including multimodality image fusion, contouring, atlas-based auto segmentation, fiber tracking and BOLD fMRI analysis, brings additional tools to account for organs-at-risk and other important anatomical and functional structures in the brain.
University of California San Francisco (UCSF) is the first institution to use iPlan pre-planning functionality with Leksell GammaPlan. Andrew T. Parsa MD, PhD, UCSF Professor and Vice Chairman of Neurological Surgery comments: “We are very excited at the possibility to complement our Gamma Knife radiosurgery treatment planning with advanced software features that have already provided an impact within our surgical environment.”
Igor J. Barani, M.D., UCSF Clinical Research Director and Vice Chair, Department of Radiation Oncology, adds: “With the iPlan RT data enrichment enabled for GammaPlan, we get additional tools to optimize functional sparing and the best ablative treatment for tumors.”
With more than 300 Leksell Gamma Knife systems in clinical use and more than 600,000 patients treated to date, Elekta is the world leader in intracranial radiosurgery, renowned for the precision and ease of use of the treatment planning and delivery system.
Commenting on the collaboration, Åsa Hedin, Executive Vice President, Elekta Neuroscience says, “iPlan offers additional options to prepare data for treatment planning in GammaPlan. Many Gamma Knife users are already familiar with iPlan, and may now choose to also use the pre-planning tools in conjunction with Gamma Knife radiosurgery. In addition, this collaboration enables neurosurgeons who use Brainlab navigation to interact more easily with Gamma Knife radiosurgery.”
Both Elekta and Brainlab will demonstrate the interface between iPlan pre-planning and Leksell GammaPlan treatment planning at the ongoing CNS meeting in Chicago.
Brainlab develops, manufactures and markets software-driven medical technology with the aim of optimizing patient treatments. Core products revolve around less-invasive image guided surgery technology, more accurate and effective radiation therapy, and integration through planning and collaboration systems that brings patient data and physicians together. www.brainlab.com
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care.
Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,400 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb.
For further information, please contact:
Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770 670 2447, email: [email protected]
Johan Andersson Melbi, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, email: [email protected]
Paula Moggio, Brainlab
Tel: +1 323 762 2434 (d); +1 626 319 6919 (m), [email protected]